A Year of Purpose and Progress: Dr. Christina Rahm Celebrates Global Growth, Scientific Breakthroughs, and International Honors 
ProMIS Neurosciences Announces Reverse Stock Split
Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for...
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and...
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card...
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027Financing anchored...
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to...
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
New findings from Phase 2 adjunctive study evaluating the characteristics of OFF time improvement with solengepras, a novel, non-dopaminergic GPR6...
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel...
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company...
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced...
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period...
LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services...
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need...
HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing
NAPLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB:HLYK), a patient-centric healthcare technology company, announced today...
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
Grant funding will support continued progress on a preclinical research program to identify and develop a non-hormonal intravaginal contraceptive innovation...
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset...
Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million
CHARLOTTE, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company...
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug...
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s...
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in...
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision...